(News Bulletin 247) – HC Wainwright initiated coverage of the Sensorion stock this week with a buy recommendation and a target of three euros.
In a research note published on Tuesday, the American research department praises the positioning found by Sensorion in the market for the treatment of hearing loss, reinforced according to him by recent clinical studies and the obtaining of new financing.
In its study, the research firm particularly welcomes the entry into the capital of Redmile, a Californian investor in the field of health, now the company’s largest shareholder.
According to HC Wainwright, the arrival of this ‘benchmark’ investor sends a favorable signal to the market and could lead to the arrival of other investors based in the United States soon.
The analyst also notes that two biotechs that are direct competitors of Sensorion were very recently acquired by ‘big pharmas’, namely Akouos taken over by Eli Lilly at the end of 2022 and Decibel acquired by Regeneron last month.
For Wainwright, these transactions reinforce Sensorion’s status as a possible target for a possible takeover, with the research department considering Novartis as the most likely buyer given its strong presence in Europe and its know-how in hearing loss and gene therapies.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
